Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41

Vaccine

Volumn 25, Issue 11, 2007, Pages 2074-2084

  Lemiale, Franck ^a   Haddada, Hedi ^a   Nabel, Gary J ^a   Brough, Douglas E ^b   King, C Richter ^b   Gall, Jason G D ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b GENVEC INC   (United States)

Author keywords

Adenovirus; Human Immunodeficiency Virus; Vaccine vector

Indexed keywords

ADENOVIRUS VECTOR; CYTOKINE; IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADENOVIRUS; ADENOVIRUS 41; ADENOVIRUS 5; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; ENVELOPE GENE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS ENVELOPE; VIRUS EXPRESSION; VIRUS GENE; VIRUS RECOMBINANT;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HUMANS; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; VACCINATION; VACCINES, SYNTHETIC;

EID: 33846857302     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.11.025     Document Type: Article

References (52)

1. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., and Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408 6812 (2000) 605-609
2. Sullivan N.J., Geisbert T.W., Geisbert J.B., Xu L., Yang Z.Y., Roederer M., et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424 6949 (2003) 681-684
3. Shiver J.W., and Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55 (2004) 355-372
4. Couch R.B., Chanock R.M., Cate T.R., Lang D.J., Knight V., and Huebner R.J. Immunization with Types 4 and 7 Adenovirus by Selective Infection of the Intestinal Tract. Am Rev Respir Dis 88 Suppl. (1963) 394-403
5. Top Jr. F.H., Dudding B.A., Russell P.K., and Buescher E.L. Control of respiratory disease in recruits with types 4 and 7 adenovirus vaccines. Am J Epidemiol 94 2 (1971) 142-146
6. Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol 7 4 (1987) 265-276
7. Mestecky J., Michalek S.M., Moldoveanu Z., and Russell M.W. Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans. Behring Inst Mitt 98 (1997) 33-43
8. Neutra M.R., and Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6 2 (2006) 148-158
9. Christensen M.L. Human viral gastroenteritis. Clin Microbiol Rev 2 1 (1989) 51-89
10. Uhnoo I., Wadell G., Svensson L., and Johansson M.E. Importance of enteric adenoviruses 40 and 41 in acute gastroenteritis in infants and young children. J Clin Microbiol 20 3 (1984) 365-372
11. Favier A.L., Burmeister W.P., and Chroboczek J. Unique physicochemical properties of human enteric Ad41 responsible for its survival and replication in the gastrointestinal tract. Virology 322 1 (2004) 93-104
12. Yeh H.Y., Pieniazek N., Pieniazek D., Gelderblom H., and Luftig R.B. Human adenovirus type 41 contains two fibers. Virus Res 33 2 (1994) 179-198
13. Pieniazek N.J., Slemenda S.B., Pieniazek D., Velarde Jr. J., and Luftig R.B. Human enteric adenovirus type 41 (Tak) contains a second fiber protein gene. Nucleic Acids Res 18 7 (1990) 1901
14. Albinsson B., and Kidd A.H. Adenovirus type 41 lacks an RGD alpha(v)-integrin binding motif on the penton base and undergoes delayed uptake in A549 cells. Virus Res 64 2 (1999) 125-136
15. Roelvink P.W., Lizonova A., Lee J.G., Li Y., Bergelson J.M., Finberg R.W., et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 72 10 (1998) 7909-7915
16. Schoggins J.W., Gall J.G., and Falck-Pedersen E. Subgroup B and F fiber chimeras eliminate normal adenovirus type 5 vector transduction in vitro and in vivo. J Virol 77 2 (2003) 1039-1048
17. de Jong J.C., Wigand R., Kidd A.H., Wadell G., Kapsenberg J.G., Muzerie C.J., et al. Candidate adenoviruses 40 and 41: fastidious adenoviruses from human infant stool. J Med Virol 11 3 (1983) 215-231
18. Brough D.E., Lizonova A., Hsu C., Kulesa V.A., and Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 70 9 (1996) 6497-6501
19. Abrahamsen K., Kong H.L., Mastrangeli A., Brough D., Lizonova A., Crystal R.G., et al. Construction of an adenovirus type 7a E1A-vector. J Virol 71 11 (1997) 8946-8951
20. Nan X., Peng B., Hahn T.W., Richardson E., Lizonova A., Kovesdi I., et al. Development of an Ad7 cosmid system and generation of an Ad7deltaE1deltaE3HIV(MN) env/rev recombinant virus. Gene Ther 10 4 (2003) 326-336
21. Jarecki-Khan K., and Unicomb L.E. Seroprevalence of enteric and nonenteric adenoviruses in Bangladesh. J Clin Microbiol 30 10 (1992) 2733-2734
22. Shinozaki T., Araki K., Ushijima H., and Fujii R. Antibody response to enteric adenovirus types 40 and 41 in sera from people in various age groups. J Clin Microbiol 25 9 (1987) 1679-1682
23. Saderi H., Roustai M.H., and Sabahi F. Antibodies to enteric adenoviruses (Ad40 and Ad41) in sera from Iranian children. J Clin Virol 16 2 (2000) 145-147
24. Kidd A.H., Banatvala J.E., and de Jong J.C. Antibodies to fastidious faecal adenoviruses (species 40 and 41) in sera from children. J Med Virol 11 4 (1983) 333-341
25. Sambrook J., and Russell D.W. Molecular Cloning: A Laboratory Manual (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
26. McVey D., Zuber M., Ettyreddy D., Brough D.E., and Kovesdi I. Rapid construction of adenoviral vectors by lambda phage genetics. J Virol 76 8 (2002) 3670-3677
27. Graham F.L., Smiley J., Russell W.C., and Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36 1 (1977) 59-74
28. Cleghon V., Piderit A., Brough D.E., and Klessig D.F. Phosphorylation of the adenovirus DNA-binding protein and epitope mapping of monoclonal antibodies against it. Virology 197 2 (1993) 564-575
29. Mittereder N., March K.L., and Trapnell B.C. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70 11 (1996) 7498-7509
30. Kong W.P., Huang Y., Yang Z.Y., Chakrabarti B.K., Moodie Z., and Nabel G.J. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 77 23 (2003) 12764-12772
31. Yang Z.Y., Chakrabarti B.K., Xu L., Welcher B., Kong W.P., Leung K., et al. Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. J Virol 78 8 (2004) 4029-4036
32. Shayakhmetov D.M., Gaggar A., Ni S., Li Z.Y., and Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 79 12 (2005) 7478-7491
33. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172 10 (2004) 6290-6297
34. Casimiro D.R., Bett A.J., Fu T.M., Davies M.E., Tang A., Wilson K.A., et al. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 78 20 (2004) 11434-11438
35. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P., et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 170 3 (2003) 1416-1422
36. Bangari D.S., Shukla S., and Mittal S.K. Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem Biophys Res Commun 327 3 (2005) 960-966
37. Loser P., Hofmann C., Both G.W., Uckert W., and Hillgenberg M. Construction, rescue, and characterization of vectors derived from ovine atadenovirus. J Virol 77 22 (2003) 11941-11951
38. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77 11 (2003) 6305-6313
39. Barouch D.H., McKay P.F., Sumida S.M., Santra S., Jackson S.S., Gorgone D.A., et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 77 16 (2003) 8729-8735
40. Lemiale F., Kong W.P., Akyurek L.M., Ling X., Huang Y., Chakrabarti B.K., et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 77 18 (2003) 10078-10087
41. Yang Z.Y., Wyatt L.S., Kong W.P., Moodie Z., Moss B., and Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 77 1 (2003) 799-803
42. Mack C.A., Song W.R., Carpenter H., Wickham T.J., Kovesdi I., Harvey B.G., et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 8 1 (1997) 99-109
43. Mastrangeli A., Harvey B.G., Yao J., Wolff G., Kovesdi I., Crystal R.G., et al. "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 7 1 (1996) 79-87
44. Kass-Eisler A., Falck-Pedersen E., Alvira M., Rivera J., Buttrick P.M., Wittenberg B.A., et al. Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo. Proc Natl Acad Sci USA 90 24 (1993) 11498-11502
45. Pieniazek D., Pieniazek N.J., Macejak D., Coward J., Rayfield M., and Luftig R.B. Differential growth of human enteric adenovirus 41 (TAK) in continuous cell lines. Virology 174 1 (1990) 239-249
46. Takiff H.E., Straus S.E., and Garon C.F. Propagation and in vitro studies of previously non-cultivable enteral adenoviruses in 293 cells. Lancet 2 8251 (1981) 832-834
47. Brown M., Wilson-Friesen H.L., and Doane F. A block in release of progeny virus and a high particle-to-infectious unit ratio contribute to poor growth of enteric adenovirus types 40 and 41 in cell culture. J Virol 66 5 (1992) 3198-3205
48. Favier A.L., Schoehn G., Jaquinod M., Harsi C., and Chroboczek J. Structural studies of human enteric adenovirus type 41. Virology 293 1 (2002) 75-85
49. Yeh H.Y., Pieniazek N., Pieniazek D., and Luftig R.B. Genetic organization, size, and complete sequence of early region 3 genes of human adenovirus type 41. J Virol 70 4 (1996) 2658-2663
50. Tollefson A.E., Scaria A., Hermiston T.W., Ryerse J.S., Wold L.J., and Wold W.S. The adenovirus death protein (E3-11, 6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 70 4 (1996) 2296-2306
51. Croyle M.A., Stone M., Amidon G.L., and Roessler B.J. In vitro and in vivo assessment of adenovirus 41 as a vector for gene delivery to the intestine. Gene Ther 5 5 (1998) 645-654
52. Xiang Z.Q., Gao G.P., Reyes-Sandoval A., Li Y., Wilson J.M., and Ertl H.C. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 77 20 (2003) 10780-10789